Medication Profile and Treatment Cost Estimation Among Outpatients with Schizophrenia, Bipolar Disorder, Depression, and Anxiety Disorders in Indonesia

References

• WHO. Mental disorders affect one in four people; 2001 Available from: https://www.who.int/whr/2001/media_centre/press_release/en/. Accessed 1031, 2019.
   Google Scholar
• World Health Organization. Mental disorders; 2018 Available from: https://www.who.int/news-room/fact-sheets/detail/mental-disorders. Accessed 1031, 2019.
   Google Scholar
• Statistics Indonesia. Population 15 years of age and over by age group and type of activity during the previous week, 2008–2018; 2019 Available from: https://www.bps.go.id/statictable/2016/04/04/1904/penduduk-berumur-15-tahun-ke-atas-menurut-golongan-umur-dan-jenis-kegiatan-selama-seminggu-yang-lalu-2008—2018.html. Accessed 1125, 2019.
   Google Scholar
• SI BPS. Statistical Yearbook of Indonesia. Sub-directorate of Statistical Compilation and Publication ed.; 2018.
   Google Scholar
• Ministry of Health Republic of Indonesia. National report basic health research 2018; 2018 Available from: http://labmandat.litbang.depkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf. Accessed 312, 2020.
   Google Scholar
• DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. McGraw Hill; 2011.
   Google Scholar
• Work Group on Schizophrenia. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd ed. American Psychiatric Association; 2010.
   Google Scholar
• Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206–1227. doi:10.1038/mp.2012.4722584864
   PubMed Web of Science ®Google Scholar
• Ganguly P, Soliman A, Moustafa AA. Holistic management of schizophrenia symptoms using pharmacological and non-pharmacological treatment. Front Public Heal. 2018;6(166):1–9. doi:10.3389/fpubh.2018.00166
   Web of Science ®Google Scholar
• Vieta E. Managing Bipolar Disorder in Clinical Practice: Third Edition; 2013. doi:10.1007/978-1-908517-94-4.
   Google Scholar
• Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672–1682. doi:10.1016/S0140-6736(13)60857-023663953
   PubMed Web of Science ®Google Scholar
• Grande I, De Arce R, Jiménez-Arriero MÁ, et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol. 2013;16(3):513–523. doi:10.1017/S146114571200040522717099
   PubMed Web of Science ®Google Scholar
• Chisholm-Burns MA, Schwinghammer TL, Well BG, Malone PA, Kolesar JM, DiPiro JT. Pharmacotherapy Principles & Practice. 4th ed. McGraw Hill Education; 2016.
   Google Scholar
• Mirabel-Sarron C, Giachetti R. Non pharmacological treatment for bipolar disorder. Encephale. 2012;38(4). doi:10.1016/S0013-7006(12)70094-5
   Google Scholar
• Kumar KPS, Srivastava S, Paswan S, Dutta AS. Depression - symptoms, causes, medications and therapies. Pharm Innovation. 2012;1(3):37.
   Google Scholar
• Spijker J, Van Straten A, Bockting CLH, Meeuwissen JAC, Van Balkom AJLM. Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: a systematic review. Can J Psychiatry. 2013;58(7):386–392. doi:10.1177/07067437130580070323870720
   PubMed Web of Science ®Google Scholar
• Wang S-M, Han C, Bahk W-M, et al. Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J. 2018;54(2):101. doi:10.4068/cmj.2018.54.2.10129854675
   PubMedGoogle Scholar
• Wells BG, DiPiro JT, Schwinghammer TL, Dipiro CV. Pharmacotherapy Handbook. 9th ed. New York: McGraw Hill Education; 2015.
   Google Scholar
• Gartlehner G, Wagner G, Matyas N, et al. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open. 2017;7(6):e014912. doi:10.1136/bmjopen-2016-014912
   Web of Science ®Google Scholar
• Park S-C, Oh HS, Oh D-H, et al. Evidence-based, non-pharmacological treatment guideline for depression in Korea. J Korean Med Sci. 2014;29(1):12–22. doi:10.3346/jkms.2014.29.1.1224431900
   PubMed Web of Science ®Google Scholar
• Victoria Institute of Strategic Economic Studies. The economic cost of serious mental illness and comorbidities in Australia and New Zealand. R Aust New Zeal Coll Psychiatr. 2016:1–48. Available from: https://www.ranzcp.org/Files/Publications/RANZCP-Serious-Mental-Illness.aspx. Accessed March 12, 2020.
   Google Scholar
• Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: A systematic review and meta-analysis. Int J Obes. 2010;34(3):407–419. doi:10.1038/ijo.2009.252
   PubMed Web of Science ®Google Scholar
• Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011;12(16):2457–2467. doi:10.1517/14656566.2011.61849621950420
   PubMed Web of Science ®Google Scholar
• Lampe L. Drug treatment for anxiety. Aust Prescr. 2013;36(6):186–189. doi:10.18773/austprescr.2013.076
   Google Scholar
• Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adults and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–1070. doi:10.1080/14656566.2018.149196630056792
   PubMed Web of Science ®Google Scholar
• Bystritsky A, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorder. Pharm Ther. 2013;38(1):30–57.
   Google Scholar
• Combs H, Markman J. Anxiety disorders in primary care. Med Clin North Am. 2014;98(5):1007–1023. doi:10.1016/j.mcna.2014.06.00325134870
   PubMed Web of Science ®Google Scholar
• Cottraux J. Nonpharmacological treatments for anxiety disorders. Dialogues Clin Neurosci. 2002;4(3):305–319.22034140
   PubMedGoogle Scholar
• Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327–337. doi:10.3350/cmh.2014.20.4.32725548737
   PubMedGoogle Scholar
• Trautmann S, Rehm J, Wittchen H. The economic costs of mental disorders. EMBO Rep. 2016;17(9):1245–1249. doi:10.15252/embr.20164295127491723
   PubMed Web of Science ®Google Scholar
• Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800. doi:10.1016/S0140-6736(15)60692-426063472
   PubMed Web of Science ®Google Scholar
• Goetzel RZ, Roemer EC, Holingue C, et al. Mental health in the workplace: a call to action proceedings from the mental health in the workplace-public health summit. J Occup Environ Med. 2018;60(4):322–330. doi:10.1097/JOM.000000000000127129280775
   PubMed Web of Science ®Google Scholar
• Bloom D, Cafero E, Jané-Llopis E, et al. The global economic burden of non-communicable diseases. Geneva: world Economic Forum; 2011 Available from: http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf. Accessed 1125, 2019.
   Google Scholar
• Mangalore R, Knapp M. Cost of Schizophrenia. J Ment Health Policy Econ. 2007;10(1):23–41.17417045
   PubMed Web of Science ®Google Scholar
• Dilsaver SC. An estimate of the minimum economic burden of bipolar i and II disorders in the United States: 2009. J Affect Disord. 2011;129(1–3):79–83. doi:10.1016/j.jad.2010.08.03020888048
   PubMed Web of Science ®Google Scholar
• Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45–51. doi:10.1016/j.jad.2017.09.01128961441
   PubMed Web of Science ®Google Scholar
• Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–2646. doi:10.1001/jama.2016.1688528027366
   PubMed Web of Science ®Google Scholar
• Sado M, Takechi S, Inagaki A. et al. Cost of anxiety disorders in Japan in 2008: a prevalence-based approach. BMC Psychiatry. 2013:13. doi:10.1186/1471-244X-13-338.23297686
   PubMed Web of Science ®Google Scholar
• Okpataku CI, Tawani D, Article O. Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic. Trends Psychiatry Psychother. 2017;39(3):165–172. doi:10.1590/2237-6089-2016-008828876362
   PubMedGoogle Scholar
• Khan A, Iqbal Z, Sultan SM, Nazar Z, Tariq M. Antipsychotic prescription patterns and treatment costs of schizophrenia in northwestern Pakistan: a one-year observational study. Trop J Pharm Res. 2018;17:339–344.
   Web of Science ®Google Scholar
• Irene M. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia publisher’ s pdf, also known as version of record publication date. J Affect Disord. 2012;140(1):38–47. doi:10.1016/j.jad.2011.10.01422099566
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental H. Bipolar Disorder: The NICE Guideline on the Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. Leicester: The British Psychological Society & The Royal College of Psychiatrists; 2014.
   Google Scholar
• Chawla S, Agarwal M, Sharma S, Jiloha RC. Drug utilization study of psychotropic drugs among psychiatric outpatients in a tertiary care hospital. Indian J Pharm Sci. 2017;79(6):1008–1013. doi:10.4172/pharmaceutical-sciences.1000319
   Web of Science ®Google Scholar
• Holzapfel EM, Szabo CP. Pharmacotherapy prescribing patterns in the treatment of bipolar disorder in a South African outpatient population. Glob Psychiatry. 2018;1(2):39–51. doi:10.2478/gp-2018-0006
   Google Scholar
• National Institute for Health and Care Excelence. Bipolar disorder: assessment and management; 2014 Available from: https://www.nice.org.uk/guidance/cg185/chapter/1-Recommendations. Accessed 1125, 2019.
   Google Scholar
• Taylor D, Paton C, Kapur S. Prescribing Guidelines in Psychiatry. 11th ed. Wiley-Blackwell; 2012.
   Google Scholar
• Turner TL. The use of antipsychotics in maintenance treatment of bipolar disorder. Ment Heal Clin. 2013;2(12):412–415. doi:10.9740/mhc.n155513
   Google Scholar
• Rossatria E. Evaluation of Antidepressants Drug Prescribing for Depressed Patients at Pharmacy Installation Outpatient in Regional Hospital Dr. Soehadi Prijonegoro Sragen; 2016.
   Google Scholar
• Yuniastuti. Evaluation of Antidepressant Drug for Therapy Patient In Depression Mental Hospital Surakarta 2011–2012; 2013.
   Google Scholar
• Ogawa Y, Takeshima N, Hayasaka Y, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;2019(6). doi:10.1002/14651858.CD001026.pub2
   Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - First revision. World J Biol Psychiatry. 2008;9(4):248–312. doi:10.1080/1562297080246580718949648
   PubMed Web of Science ®Google Scholar
• Farach FJ, Pruitt LD, Jun JJ, Jerud AB, Zoellner LA, Roy-Byrne PP. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord. 2012;26(8):833–843. doi:10.1016/j.janxdis.2012.07.00923023162
   PubMed Web of Science ®Google Scholar
• Tanguay Bernard MM, Luc M, Carrier JD, et al. Patterns of benzodiazepines use in primary care adults with anxiety disorders. Heliyon. 2018;4(7). doi:10.1016/j.heliyon.2018.e00688
   Web of Science ®Google Scholar
• Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological management of anxiety disorders in the elderly. Curr Treat Options Psychiatry. 2017;4(1):33–46. doi:10.1007/s40501-017-0102-428948135
   PubMedGoogle Scholar
• Ellen S, Selzer R, Norman T, Blashki G. Depression and anxiety: pharmacological treatment in general practice. Aust Fam Physician. 2007;36(4):222–228.17392933
   PubMedGoogle Scholar
• Ye W. Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’ s Republic of China. Neuropsychiatr Dis Treat. 2015;11:983–990.25897235
   PubMed Web of Science ®Google Scholar
• Oloniniyi IO, Akinsulore A, ALoba OO, Mapayi BM, Oginni OA, Makanjuola R. Economic cost of schizophrenia in a Nigerian Teaching Hospital. J Neurosci Rural Pract. 2019;10(1):39–47. doi:10.4103/jnrp.jnrp_210_1830765969
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB-C, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373. doi:10.2147/NDT.S9664926937191
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mathan K, Sakey S, Shaik S, Subramanian K, Kattimani S. Cost-of-treatment of clinically stable severe mental lilnesses in India. Indian J Soc Psychiatry. 2017;33(3):262. doi:10.4103/0971-9962.214600
   Google Scholar
• Cloutier M, Greene M, Guerin A, Touya M, Wu E. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;15(226):45–51. doi:10.1016/j.jad.2017.09.011
   Web of Science ®Google Scholar
• Okumura Y, Higuchi T. Cost of depression among adults in Japan. Prim Care Companion CNS Disord. 2011;13(3):PCC.10m01082. doi:10.4088/PCC.10m01082
   Google Scholar
• Shirneshan E, Bailey J, Relyea G, Franklin BE, Solomon DK, Brown LM. Incremental direct medical expenditures associated with anxiety disorders for the U.S. adult population: evidence from the medical expenditure panel survey. J Anxiety Disord. 2013;27(7):720–727. doi:10.1016/j.janxdis.2013.09.00924135257
   PubMed Web of Science ®Google Scholar
• Ministry of Health Republic Indonesia. Heart disease is the highest cause of death, Ministry of Health reminds the CERDIK; 2017 Available from: https://www.depkes.go.id/article/view/17073100005/penyakit-jantung-penyebab-kematian-tertinggi-kemenkes-ingatkan-cerdik.html. Accessed 1030, 2019.
   Google Scholar
• Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468. doi:10.2147/PPA.S12465828424542
   PubMed Web of Science ®Google Scholar